Your session is about to expire
← Back to Search
PGT121.414.LS for Human Immunodeficiency Virus Infection
Study Summary
This trial is testing an HIV antibody to see if it's safe, tolerable, and effective when given alone or with another HIV antibody.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Is eligibility limited to individuals under the age of 45 for this research endeavor?
"Eligible patients for this study must be between the age of majority and 50 years old."
Are recruitment efforts for this experiment ongoing?
"The information on clinicaltrials.gov shows that this particular trial has concluded its recruitment phase and is no longer accepting patients. It was initially posted in October 2020, with the last update occurring at the end of August 2022; however, there are still 484 other trials actively recruiting right now."
What is the number of locations participating in this experiment?
"This clinical research is occurring at George Washington University in the District of Columbia, The Hope Clinic of Emory Vaccine Center in Decatur, Georgia, and UCLA CARE Centre in Los Angeles. Additionally there are 6 additional sites running this trial."
Might I be eligible to join this clinical trial?
"This clinical trial is looking to enrol 32 participants who have HIV and are aged between 18-50. To qualify, they must be willing to discuss HIV infection risks and partake in risk reduction counselling; demonstrate general good health through medical history, physical exam and screening lab tests; receive their HIV test results; as well as commit to a low-risk behaviour until the last required protocol clinic visit. Additionally, no other investigational research agent can be enrolled in until completion of this study's final visits."
What is the intended outcome of this research?
"The primary endpoint of this trial will be assessed by Month 8 and is the magnitude of serum neutralizing activity, as measured with monoclonal antibody (mAb)-specific Env-pseudotyped viruses in TZM-bl cells. Secondary objectives include measuring the magnitude of neutralising activity against a panel of reference virus pseudotypes in TZM-bl cells at specified timepoints for participants from all groups; assessing serum concentrations of VRC07-523LS at prearranged intervals; and also recording Anti-drug antibodies (ADA) titres during predetermined times for every participant regardless how many product administrations they have received"
Has the FDA authorized PGT121.414.LS for public consumption?
"With minimal data verifying PGT121.414.LS's safety and efficacy this medication garnered a score of 1 on our team's rating scale from 1 to 3."
Share this study with friends
Copy Link
Messenger